Human Broadly Neutralizing Monoclonal Antibodies associated with Hepatitis C Virus Clearance

Peak revenue. There is no defensible standalone-product peak for this asset. The therapeutic HCV market was collapsed by direct-acting antivirals (>95% SVR; sofosbuvir/Epclusa-class), and the only historical antibody niches — peri-transplant recurrence prophylaxis (MBL-HCV1, Civacir) — were abandoned because peri-transplant DAA treat-and-cure removed the need for passive immunization. The honest value path is licensing the bNAb/epitope panel to an HCV-vaccine developer as a reverse-vaccinology immunogen-design input; realistic value is upfront + milestones + low single-to-mid royalties on a future vaccine, not product sales. The $120M figure is a deliberately conservative illustrative envelope-anchor for cohort consistency only (it is not a forecast of antibody-drug sales) and reflects the order of magnitude of a successful licensed vaccine-enabling IP position, heavily risk-discounted; it is not the decision criterion for this asset.

WACC. A 16% rate reflects discovery-stage risk with a structurally impaired commercial path (curative DAA standard of care, two abandoned anti-HCV-E2 prophylaxis precedents, and value contingent on a still-unsolved HCV vaccine), well above a standard mainstream-biologic 12%.

This asset is not a therapeutic drug — it is a discovery-stage research output: a panel of broadly neutralizing monoclonal antibodies and their HCV E2 epitope maps, isolated by the Johns Hopkins Bailey laboratory from a single 'elite neutralizer' (subject C110) who spontaneously cleared multiple HCV infections. The published work (Immunity 2024) isolated 10,680 E2-reactive B cells and showed bNAb lineages converging on diverse conserved E2 sites; the authors and the JHU listing both frame the primary application as guiding HCV vaccine antigen design ('Candidates for discovery of HCV vaccine antigens'), with therapeutic use a distant secondary. Classified as a research_tool / reverse-vaccinology input; the rNPV envelope below is shown only for cohort consistency and is explicitly not the decision criterion, which is why the asset is classified as grant_non_commercial.

The economic frame is dominated by one fact a CMO will raise in the first minute: HCV is functionally curable with direct-acting antivirals (>95% SVR), which collapsed the therapeutic market. The only historical antibody niche — peri-transplant recurrence prophylaxis — is itself a cautionary precedent: MBL-HCV1, a target-identical anti-E2 human mAb, failed its primary endpoint in liver transplant (all subjects HCV-RNA-positive by day 42), only delayed rebound, and bred E2 escape mutants under monotherapy; the Civacir polyclonal program in the same niche was likewise superseded once peri-transplant DAA treat-and-cure removed the need for passive immunization. Against those anchors there is no standalone-product peak; the only credible value is licensing the bNAb/epitope panel to an HCV-vaccine developer for immunogen design (upfront + milestones + low royalties). The engine result is -$28.0M to -$16.4M, with a base rNPV of -$22.2M and cumulative PoS of 0.5%; that spread is illustrative cohort-consistency arithmetic, not a forecast of antibody-drug revenue, and a positive headline number here should be read as a rNPV artifact, not investability.

Verdict: scientifically excellent, commercially non-investable as a therapeutic — a grant/licensing asset, not a VC equity story. It earns its rank from rubric clinical-relevance and modality (mAb / pan-genotype neutralization) plus a neutral 'other'-indication whitespace score, not from a fundable product economic case; the rubric rank is a methodology-pinned artifact and is taken as given. The honest funding path is grant_non_commercial because the durable value is reverse-vaccinology IP licensed to a vaccine developer or supported by NIH/CEPI-type non-commercial funding, not standalone biotech equity.